Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers

Trial Profile

Long-Acting Lanreotide as a Volume Reducing Treatment of Polycystic Livers

Completed
Phase of Trial: Phase II/III

Latest Information Update: 28 Mar 2014

At a glance

  • Drugs Lanreotide (Primary)
  • Indications Polycystic liver disease
  • Focus Therapeutic Use
  • Acronyms LOCKCYST; LOCKCYST I
  • Most Recent Events

    • 28 Mar 2014 New trial record
    • 14 Feb 2008
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top